<DOC>
	<DOCNO>NCT01700673</DOCNO>
	<brief_summary>To determine impact maintenance therapy patient MDS/AML remission .</brief_summary>
	<brief_title>Phase II Study Azacitidine Sargramostim Maintenance Treatment Poor-Risk AML MDS</brief_title>
	<detailed_description>We propose phase II study determine impact maintenance therapy 5-azacytidine GM-CSF patient poor-risk AML MDS , remission definitive treatment either stem cell transplant cytarabine-based consolidation chemotherapy . In order precede relapse avoid lead time bias , treatment would need commence within 185 day definitive therapy . Furthermore , approximately 50 % relapse occur within first year 80 % within two year SCT , therefore would limit duration maintenance therapy one year , follow two year follow-up .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>1 . Age &gt; 6 month 2 . Initial diagnosis poor risk AML MDS ( define section 3.2 ) , treat either stem cell transplant cytarabinebased consolidation chemotherapy , within past 60185 day 3 . ECOG performance status 02 4 . No morphologic evidence leukemia active MDS determine JHH Hematopathologist independent review bone marrow aspirate biopsy do follow completion therapy within 14 day prior enrollment 5 . Peripheral blood count recovery : Neutrophil count ≥ 1000 /µL , platelet count ≥ 50x 109 /µL without platelet transfusion , adequate hematocrit independent red cell transfusion . 6 . No evidence extramedullary leukemia , CNS soft tissue involvement 7 . Adequate end organ function measure follow : AST ALT &lt; 4 x normal , total serum bilirubin &lt; 2 x upper limit normal ( unless due hemolysis , Gilbert 's syndrome , ineffective erythropoiesis ) , creatinine &lt; 2 x upper limit normal 8 . Ability give inform consent 9 . In agreement use effective barrier method birth control avoid pregnancy study minimum 30 day study treatment , male female patient fertile 1 . Patients untreated uncontrolled infection 2 . Patients untreated uncontrolled grade 3 4 GVHD 3 . Pregnancy lactation 4 . Concurrent use investigational agent . 5 . Known HIVpositive patient . 6 . Known hypersensitivity 5AC GMCSF</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>maintenance treatment</keyword>
	<keyword>stem cell transplant</keyword>
	<keyword>cytarabine-based chemotherapy</keyword>
</DOC>